Cancer biomarkers market seen reaching $77.37 billion by 2033

Coherent Market Insights says the global cancer biomarkers market will grow from $32.69 billion in 2026 to $77.37 billion by 2033. The forecast report highlights demand drivers, segment growth, competitive positioning and regional opportunities across diagnostics and research.

Why it matters: - Cancer biomarkers are used to detect, monitor and help guide treatment decisions across multiple cancer types. - The market forecast signals rising commercial demand for diagnostic tools, lab technologies and research platforms through 2033. - The report is positioned for businesses, investors and industry participants tracking where growth may concentrate.

What happened: - Coherent Market Insights published a new report, “Cancer Biomarkers Market Forecast 2026–2033,” on June 8, 2026. - The report estimates the global cancer biomarkers market at $32.69 billion in 2026 and projects it to reach $77.37 billion by 2033. - Coherent Market Insights made a sample copy available here. - The firm also promoted a discounted purchase option for the premium report here.

The details: - The study covers global and country-level forecasts, competitive landscape analysis and supply chain evaluation. - The report includes SWOT analysis, Porter’s Five Forces and forward-looking assessment of growth drivers, restraints, trends, opportunities and challenges. - The research breaks the market down by biomarker type, cancer type, profiling technology and end user. - Biomarker types covered include CA 125, HER2, EGFR, CD20, BRAF, calcitonin and others. - Cancer types covered include breast cancer, lung cancer, prostate cancer, kidney cancer, liver cancer, head and neck cancer, non-small cell lung cancer and other cancers. - Profiling technologies covered include OMICS technology, imaging technology, immunoassays, cytogenetics and others. - End users covered include hospitals, specialty clinics, diagnostic laboratories, academic and research institutes and others. - The report says it analyzes revenue forecasts for type and application segments for 2026–2033. - The report says it evaluates market share, revenue, product portfolio, production capacity, gross margins and sales performance for leading companies. - Companies listed include bioMérieux, INOVIQ, Bio-Rad Laboratories, Abbott, Becton Dickinson and Company, Merck KGaA, QIAGEN, Thermo Fisher Scientific, CENTOGENE, PerkinElmer, Siemens Healthineers, F. Hoffmann-La Roche, Agilent Technologies, Invitae, Myriad Genetics, Guardant Health, Illumina and Foundation Medicine. - Regional coverage spans North America, Europe, Asia-Pacific, South America and the Middle East & Africa. - The report highlights competitive developments such as expansions, product launches, acquisitions and collaborations.

Between the lines: - The report’s broad scope suggests buyers want both market sizing and a tactical map of where competition and demand may shift next. - The emphasis on segment-level forecasts points to a market where growth opportunities vary sharply by cancer type, testing method and end user. - The company’s promotion of sample access and purchase discounts indicates the report is aimed at commercial decision-makers, not just researchers.

What’s next: - Market watchers will likely focus on whether adoption of biomarker testing accelerates in major cancer categories such as breast and lung cancer. - Segment-level performance across diagnostics laboratories, hospitals and research institutes will be key indicators of where revenue concentrates. - The report’s regional breakdown sets up future comparisons across North America, Europe and Asia-Pacific as the market evolves.

The bottom line: - Coherent Market Insights is betting the cancer biomarkers market more than doubles by 2033, with growth tied to testing demand, technology shifts and competitive activity.